Â鶹´«Ã½Ó³» of Queensland congratulates ResApp Health Limited (ASX:RAP) following the company’s success at the global in Sydney last night.
The company, which is developing a smartphone medical application for the diagnosis and management of respiratory disease, won the global Best Tech IPO/Venture Capital Raising Category, having won the same category at the Award’s Asia Pacific ceremony in Melbourne last month.
The Award finalists were judged by a panel led by Apple co-founder Steve Wozniak.
ResApp was established in 2014 based on technology developed by Â鶹´«Ã½Ó³»’s Associate Professor from the .
The award follows the company’s recent announcement that it is planning a clinical study at Massachusetts General Hospital (MGH) a 1,000-bed academic medical centre in Boston (US).
Dr Dean Moss, chief executive of Â鶹´«Ã½Ó³»’s main commercialisation company said he was delighted to see ResApp’s success recognised on the world stage.
“This Award represents the global recognition of the quality of Â鶹´«Ã½Ó³»’s research and the excellent work ResApp has done in developing a product that is set to revolutionise the diagnosis and management of respiratory disease around the world.
“We are very proud of the success the company has achieved to date and will continue to watch their progress with great interest,” Dr Moss said.
Since listing on the Australian Stock Exchange in mid 2015, the company has raised more than $16 million.
UniQuest media: Nicole Cowan – n.cowan@uniquest.com.au; +61 409 767 199
